Search

Displaying results 2371 - 2380 of 10000 in total
  1. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    Ferric carboxymaltose is an iron replacement product and, chemically, an iron-carbohydrate complex. It was FDA approved on July 25, 2013.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. … Limaprost alfadex has been shown to improve peripheral circulatory failure with a vasodilator action and an antithrombotic effect.

  3. Drug

    Amikacin

    go.drugbank.com/drugs/DB00479
    ApprovedInvestigationalVet approved

    Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A. … [FDA label] Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.

    Synonyms: 1-N-(L(−)-γ-amino-α-hydroxybutyryl)kanamycin ACategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  4. Target

    Inositol 1,4,5-trisphosphate-gated calcium channel ITPR2

    go.drugbank.com/bio_entities/BE0009594
    TargetHumans

    Inositol 1,4,5-trisphosphate-gated calcium channel that upon inositol 1,4,5-trisphosphate binding transports calcium from the endoplasmic reticulum lumen to cytoplasm. Exists in two states; a long-lived closed state where the channel is ...

    Synonyms: IP3 receptor isoform 2, Type 2 InsP3 receptor
  5. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index
  6. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339] … [L51319] On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known as TPP1 deficiency.

  7. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    a potential therapeutic target. … [A216183] Topical pediculicides generally lack adequate ovicidal activity,[A216183] including standard-of-care treatments such as [permethrin], and many require a second administration 7-10 days following

  8. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. … [A230123] The increased potency makes melphalan flufenamide a treatment option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of therapy already.

  9. Drug

    Zinc acetate

    go.drugbank.com/drugs/DB14487
    ApprovedInvestigational

  10. Drug

    Melatonin

    go.drugbank.com/drugs/DB01065
    ApprovedInvestigationalNutraceuticalVet approved

    Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. … The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus

    Categories: Compounds used in a research, industrial, or household setting, Melatonin Receptor Agonists